Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced its entrance into a definitive agreement with SoluBest Ltd. to acquire the worldwide rights for the use, development and commercialization of its patented Solumer™ Oral Drug Delivery Technology. The innovative technology will be employed to improve the bioavailability, delivery and commercialization of biocannabis-based products. The delivery technology also encompasses SoluCBD and SoluTHC, ingredients for a new category of cannabis-infused non-alcoholic beverages. “The addition of Solumer™ further positions us to collaborate with multinational companies to introduce non-alcoholic cannabis-infused beverages to consumers. Pivot has the largest portfolio of platform technologies for the formulation and delivery of cannabinoids in the cannabis space,” Pivot Pharmaceuticals CEO Dr. Patrick Frankham stated in the news release. “As we prepare to bring Pivot’s industry leading pipeline of derivatives to market, we continue to aggressively execute on our business plan.”
To view the full press release, visit http://ibn.fm/P5sZH
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot’s wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired worldwide rights to Ready-To-Infuse Cannabis (“RTIC”) oil-to-powder technology, BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (“CBD”), and tetrahydrocannabinol (“THC”)-based products. For more information, visit the company’s website at www.PivotPharma.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
